AI Summary
The article discusses how clinical trials for new cancer drugs may be excluding individuals with the Duffy-null phenotype, which is common among people of African or Middle Eastern descent. This exclusion could lead to disparities in access to potentially life-saving treatments.
Many clinical trials of new cancer drugs may be inappropriately excluding some people with Duffy-null phenotype, a trait found predominantly in people of African or Middle Eastern descent, researchers report in a new study.